Inovio DNA Vaccine Candidate INO-4800 for SARS-CoV-2
Inovio (INO) announced the publication of the preclinical study data for its novel coronavirus SARS-CoV-2 DNA vaccine INO-4800 which is demonstrating robust neutralizing antibody and T cell immune responses against COVID-19.
The study was published in the peer-reviewed journal Nature Communications titled, "Immunogenicity of a . . .